Epidemiology’s coverage of dry eye disease (DED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of DED for each country, as well as annualized case counts projected to the national population. Patient populations are forecast over a period of 20 years.

DRG Epidemiology’s DED forecast will answer the following questions:

  • Of all people with DED, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with DED, how many in each of the major mature pharmaceutical markets have mild, moderate, or severe disease?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of DED over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following DED subpopulations:

  • Diagnosed mild, moderate, and severe DED.

Note: Coverage may vary by country.

Table of contents

  • Dry Eye - Epidemiology - Mature Markets Data

Author(s): Fjoralba Kristo, MD, MPH

Fjoralba Kristo has expertise in forecasting infectious diseases and chronic diseases in both the mature and global markets. She has extensive academic experience with quantitative and qualitative research methods.

Prior to joining Decision Resources Group, she completed a postdoctoral fellowship at University of Kentucky, Division of Cardiovascular Medicine, and more recently worked as Research Scientist at Massachusetts General Hospital, where she investigated mechanisms of inflammation in cardiovascular diseases. Fjoralba holds an MPH degree from Boston University School of Public Health, concentrating in Epidemiology and Biostatistics, and a medical degree from University of Medicine, Bucharest, Romania.


Related Reports

Dry Eye - Landscape & Forecast - Disease Landscape & Forecast

Dry eye disease (DED) is a chronic, inflammatory, and highly heterogeneous condition of the eye; it is also referred to as dry eye syndrome or keratoconjunctivi...

View Details

Dry Eye - Current Treatment - Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)

In dry eye disease (DED), the normal functioning of the tear film is disrupted, resulting in troublesome ocular symptoms such as eye burning, and presentin...

View Details

Dry Eye - Access & Reimbursement - Detailed, Expanded Analysis (US)

The U.S. market for dry eye disease (DED) therapies witnessed notable developments in 2019, including Novartis’s acquisition of Xiidra and the launch of S...

View Details